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Inherited retinal degeneration (RD) is a devastating and currently
untreatable neurodegenerative condition that leads to loss of
photoreceptor cells and blindness. The vast genetic heterogeneity
of RD, the lack of “druggable” targets, and the access-limiting
blood–retinal barrier (BRB) present major hurdles toward effective
therapy development. Here, we address these challenges (i) by tar-
geting cGMP (cyclic guanosine- 3′,5′-monophosphate) signaling, a
disease driver common to different types of RD, and (ii) by combin-
ing inhibitory cGMP analogs with a nanosized liposomal drug de-
livery system designed to facilitate transport across the BRB. Based
on a screen of several cGMP analogs we identified an inhibitory
cGMP analog that interferes with activation of photoreceptor cell
death pathways. Moreover, we found liposomal encapsulation of
the analog to achieve efficient drug targeting to the neuroretina.
This pharmacological treatment markedly preserved in vivo retinal
function and counteracted photoreceptor degeneration in three dif-
ferent in vivo RD models. Taken together, we show that a defined
class of compounds for RD treatment in combination with an in-
novative drug delivery method may enable a single type of treat-
ment to address genetically divergent RD-type diseases.
PKG | CNG channel | calpain | apoptosis | in vivo imaging
Hereditary retinal degeneration (RD) relates to a group ofrare blinding diseases in which the photoreceptors of the
retina degenerate and die. RD-type diseases, such as retinitis
pigmentosa or Leber’s congenital amaurosis, are genetically very
heterogeneous and, unfortunately, still untreatable (1, 2). Typi-
cally, these diseases first affect rod photoreceptors, which me-
diate vision under dim-light conditions. Since human vision
mostly depends on cone photoreceptors—responsible for high-
resolution color vision in bright light—rod-mediated vision is less
critical for humans, and indeed many RD patients notice the
primary loss of rods only at an advanced disease stage. However,
the loss of rods triggers the subsequent loss of cones, which then
leads to complete blindness (3). Conversely, the preservation of
rods should thus save cone-mediated vision (4).
cGMP (cyclic guanosine- 3′,5′-monophosphate) is a key molecule
for photoreceptor signal transduction and has two general cellular
effectors: cyclic nucleotide gated ion channels (CNGCs) and
cGMP-dependent protein kinase (PKG) (5). In the transduction
cycle, photoreceptor cGMP is degraded by phosphodiesterase-6
(PDE6) and accordingly a loss-of-function mutation in the rod-
specific Pde6b gene causes an excessive accumulation of cGMP in
rods, as seen for instance in the rd1 mouse model for RD (6, 7).
This cGMP accumulation brings on rapid rod cell death and
eventually secondary loss of cones (8).
Abnormally high levels of cGMP in photoreceptors are a
common feature in several genetically different forms of RD (6,
7, 9–13). Moreover, the cGMP effector PKG is overactivated in
mutant photoreceptors and experimental PKG activation alone
is sufficient to cause photoreceptor death in WT retina (7). The
second major cGMP effector, the CNGCs, play an integral role
in phototransduction, as they enable the influx of Na+ and Ca2+,
linking the transduction cascade to changes in photoreceptor
membrane potential. CNGC beta subunit deletion protects rd1
photoreceptors (14), suggesting that also CNGCs contribute
to the disease progression. Here, the mechanism probably in-
volves increased Ca2+ influx and subsequent activation of Ca2+-
dependent calpain-type proteases (15), including proteolytic
activation of apoptosis-inducing factor (AIF) (16). cGMP-
dependent overactivation of PKG and CNGC in photoreceptors
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may, thus, qualify as critical disease drivers, making them promising
candidates for a targeted molecular intervention therapy for RD (17).
To address the “targetability” of PKG and CNGC we have
produced and tested cGMP analogs that inhibit these proteins.
We devised a multilevel approach, in which cGMP analogs were
designed, synthesized, and then screened in biological systems of
increasing complexity. We first investigated cGMP analog effects
in photoreceptor-like cells in vitro, then in organotypic retinal
explant cultures and acute retinal slice preparations, and finally
in vivo. In the living animal, the photoreceptor cells reside be-
hind the blood–retinal barrier (BRB) (18). To overcome this
barrier, a liposomal drug delivery vehicle was used, to facilitate
transfer of cGMP analogs into the retina (19).
With this workflow, we identified a liposomal (LP) cGMP
analog formulation, LP-CN03, which markedly preserved in vivo
retinal function and reduced rod photoreceptor loss in three
different RD models. Targeting cGMP signaling in this way not
only protected rods affected by different causative mutations but
also resulted in functional preservation of cones. In combination
with liposomal delivery this approach offers a starting point for
the development and translation of a pharmacological therapy
with defined molecular targets.
Results
To investigate the potential of cGMP analogs as a new phar-
macological class for the treatment of RD we took advantage of
the possibilities to modify these compounds so that they could
inhibit PKG and/or CNGC.
Development of cGMP Analogs. RP-configurated phosphorothioate-
modified cGMP (RP-cGMPS; SI Materials and Methods) analogs are
classified as inhibitors of PKG, regardless of other nucleobase modi-
fications (20, 21). The introduction of the β-phenyl-1,N2-etheno-
modification (PET) onto the RP-cGMPS backbone additionally in-
hibits photoreceptor CNGC (22). In contrast,RP-cGMPS analogs with
modifications in position 8 (C-8) alone are CNGC activators (23).
We used two parallel strategies for designing RP-cGMPS an-
alogs (Fig. 1A). First, we employed C-8 substituents either alone
or in combination with the PET motif. Second, we evolved
alternatives of the PET moiety, containing substituents that
Fig. 1. Structures of mono- and dimeric cGMP an-
alogs and flow chart for biological activity testing.
(A) Illustration of monomers is reduced to the
modifications introduced. R1 + R2 (yellow highlight)
include the PET modifications, R3 (green) refers to
the 8 position (C-8) of cGMP, and a sulfur atom at R4
(red) establishes the RP-configurated phosphor-
othioate. (B) Stepwise compound screening in sys-
tems of increasing biological complexity. At each
step compounds were filtered out based on
photoreceptor-specific readouts, with only CN03 and
its liposomal formulation (LP-CN03) reaching the in
vivo stage.
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connect positions 1 and N2 of the guanine nucleobase as well as
substituents solely bound to position 1. These two strategies led
to the generation of a set of RP-cGMPS structures, most of them
with strongly increased lipophilicity compared with the parent
compound cGMP (Table 1).
To further improve potency and specificity, a strategy origi-
nally described for activatory cGMP-analogs (24) was extended
to inhibitory cGMP analogs, where a polymer- (e.g., PEG)
linked dimer with equal or different RP-cGMPS analogs at its
ends formed a so-called spanning clamp (Fig. 1A). Such in-
hibitory clamps are expected to simultaneously block two
cGMP binding sites of CNGC or PKG by using a combination
of PET- and 8-substituents with correspondingly slow off-rates
after binding (24).
Table 1. Lipophilicity data and putative effect of Rp-cGMPS analogs
Compound Analog log k′g rLcGMP* Effect on PKG Effect on CNGC
A cGMP 0.770 1.0 + +
B RP-cGMPS 0.894 1.3 − +
C RP-8-Br-cGMPS 1.285 3.3 − +
CN01 8-pCPT-cGMP 2.520 56 + +
CN02 RP-8-pCPT-cGMPS 2.610 69 − +
CN03 RP-8-Br-PET-cGMPS 2.831 115 − −
CN04 RP-8-pCPT-PET-cGMPS 3.530 575 − ±†
CN05 RP-8-pHPT-PET-cGMPS 3.078 203 − ±†
CN06 RP-8-pIPrPT-PET-cGMPS 3.815 1,109 − ±†
CN07 RP-8-Br-(3-Tp)ET-cGMPS 2.746 95 − −
CN08 RP-8-oAPT-cGMPS 1.974 16 − +
CN09 RP-cGMPS-8-TMAmd-(EO)8-EAmdMT-8-RP-cGMPS 2.039
‡ 19 − +
CN10 PET-RP-cGMPS-8-TMAmd-(EO)8-EAmdMT-8-RP-cGMPS-PET 3.236
‡ 292 − ±†
“+” indicates a PKG/CNGC activator; “−” indicates inhibitor.
*Relative lipophilicity of Rp-cGMPS analog compared with cGMP.
†No distinct assignment as CNGC inhibitor, as large substituents in 8 position tend to activate CNGC and might overrule inhibition induced
by PET or PET-like substitution.
‡Values for dimeric analogs are not directly comparable with values for monomeric analogs.
Fig. 2. Screening of cGMP analogs in vitro. cGMP
analogs were tested in retinal neurosphere-derived
rod photoreceptor-like cell cultures (A–E) and orga-
notypic retinal explant cultures (F and G). NT, not
treated. (A) rd1 mutant photoreceptor-like cell cul-
tures treated with 50 μM of the respective compound
until DIV11 (red, ethidium homodimer staining; blue,
nuclear counter staining). (B) Percentage of ethidium
homodimer-labeled, dying photoreceptor-like cells
[green, WT; red, rd1; yellow, different analog treat-
ments; n = 5–62 cell culture samples obtained from
two to seven independent preparations; red asterisks
indicate toxic effect (i.e., more dying cells compared
with NT)]. (C and D) Dose–response curves for CN02–
CN07 starting at attomolar concentration. (E) EC50
values for CN02–CN07 calculated from dose–response
curves. (F) TUNEL assay (red) on vertical sections from
P11 retinal cultures NT or treated with 50 μM of the
respective compound. (G) Ratio (treated/NT) of TUNEL-
labeled cells (same color code as in B, WT, n = 9 sepa-
rate retinal explant cultures; rd1: NT, 22; CN02, 8; CN03,
8; CN04, 8; CN05, 6; CN06, 4; CN07, 8). Error bars: SEM.
Statistical comparisons: B and G, NT-rd1 vs. treated rd1
using one-way ANOVA with Holm–Sidak’s multiple-
comparisons test; ONL, outer nuclear layer contain-
ing rod and cone photoreceptor nuclei. (Scale bars: A,
100 μm; F, 50 μm.) *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.













Ten cyclic nucleotides were generated and denominated
CN01–CN10. Previous work (20–22) had established the R4 oxo-
substituted compound CN01 as a PKG and CNGC activator. The
phosphorothioates CN02–CN10 were suggested to inhibit PKG.
Compounds CN02, CN08, and CN09 were predicted to activate,
and the remaining compounds to inhibit, CNGC. The absolute
and relative lipophilicity was measured, and the compounds were
grouped according to their structural motifs (PET and C-8) (20–
22) and their predicted inhibitory patterns (Table 1) and then
forwarded to testing in rod photoreceptor-like cell cultures as a
prescreen for biological activity (Fig. 1B).
Screening of cGMP Analogs in Cell and Tissue Models for RD in Vitro.
Primary rod photoreceptor-like cell cultures were derived from
mice carrying the rd1 mutation in Pde6b (16). Here, cells
expressing rhodopsin (i.e., rod photoreceptors) undergo spon-
taneous cell death, with a peak of cell demise at day in vitro
(DIV) 11. Rhodopsin-expressing cells have functional CNGC (16,
25), display increased intracellular cGMP levels compared with
WT cells, and express all three PKG isoforms (PKG1α, 1β, and 2;
Fig. S1). We used these rd1 cell cultures as a rapid in vitro com-
pound screening system by exposing them to different cGMP
analogs and evaluating their effect on cell death at DIV11 using
ethidium homodimer staining (Fig. 2A and Fig. S2A). For com-
parison, we tested CN01, the oxo-form of CN02 and activator of
PKG and CNGC, which had no effect on cell death. In contrast,
the RP-configurated sulfur forms (i.e., PKG inhibitors) CN02–
CN07 showed significant protective effects at a concentration of
50 μM. At the same time CN08 and CN09 did not protect rd1
cells, while CN10 was toxic at 50 μM (Fig. 2B). Dose–response
curves were obtained for CN02–CN07 and were used to calculate
the corresponding EC50 values (Fig. 2 C–E). Remarkably, com-
pounds CN05 and CN07 maintained their protective effects on rd1
cells down to the pico- and even femtomolar range.
Fig. 3. Effects of cGMP analogs on cone photore-
ceptor Ca2+ dynamics. (A) Vertical section of a mouse
retina, expressing the TN-XL Ca2+ biosensor (below:
magnification of cone terminals, indicated by box in
top image). (Scale bar: 20 μm.) (B) Representative
Ca2+ responses to light flashes before (green) and
during application of 50 μM of the compound in-
dicated below (yellow). (C) Compound-induced
change in Ca2+ baseline (Rbase) measured in n = 23
cones in slices obtained from three animals (23/3) for
CN02 (CN03, 18/3; CN04, 15/2; CN05, 11/2). Wash
shown in gray. (D and E) Compound-induced changes
in area under the curve, with negative values in-
dicating larger response size (D), and peak height,
with negative values indicating higher peaks (E; arbi-
trary units, a.u.). Statistical comparisons: C–E, not-
treated WT vs. treated WT using Wilcoxon matched
pairs, signed rank test. ΔR, amplitude; GCL, ganglion
cell layer; INL, inner nuclear layer containing inter-
neurons; IS, inner segments containing organelles of
photoreceptors; ONL, outer nuclear layer containing
rod and cone photoreceptor nuclei; OPL, outer plexi-
form layer; OS, outer segments of photoreceptor cells.
n.s., P > 0.05; *P ≤ 0.05, ***P ≤ 0.001.
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Compounds with significant protective activity on photoreceptor-
like cells were validated in organotypic retinal explants. This system
permits analysis of direct drug effects on photoreceptor viability
while preserving their cytological context, under defined, serum-
free conditions (7, 26). We used explants derived from rd1 mice
(Fig. 2F), which show prominent rod degeneration at postnatal (P)
day 11. The effects of CN02–CN07 on photoreceptor cell death
were assessed at P11 using the TUNEL assay. The analysis gave the
following rank order of protection: CN04 > CN03 >CN02 > CN05,
with CN06 and CN07 having no discernible effect (Fig. 2G). The
combined information from the cell and tissue levels left us with
CN02–CN05 displaying significant photoreceptor neuroprotection.
CN02–CN05 were then tested with respect to inhibition of CNGCs
and Ca2+ influx in cone photoreceptors. To this end, we used acute,
freshly prepared retinal slices from WT animals expressing the TN-
XL Ca2+ biosensor exclusively in cones (27), monitored by a two-
photon Ca2+-imaging approach (28) (Fig. 3A). Here, CN02, CN04,
and CN05 significantly increased cone Ca2+ levels, suggesting CNGC
activation. In contrast, CN03 moderately but significantly reduced
cone Ca2+ levels, likely making it a weak inhibitor of CNGC (Fig. 3 B
and C). Light-induced cone Ca2+ responses, as assessed by area
under the curve and peak amplitudes, were increased by CN02, de-
creased by CN03, and remained essentially unchanged by CN04 and
CN05 (Fig. 3 D and E). Overall, these results imply that CN02 and
CN03 kept the cone phototransduction cascade and light-induced
cone responses largely intact. We later confirmed this inter-
pretation by cone-specific electroretinography (ERG) mea-
surements (discussed below). Because long-term elevation of
photoreceptor Ca2+ levels is thought to be deleterious (29–31),
we selected CN03 as the compound for further investigations.
CN03 Engages PKG and CNGC. To investigate how CN03 exerted its
positive effect on photoreceptor survival we analyzed molecular
processes downstream of PKG and CNGC activation in rd1
photoreceptor-like cells (16). PKG phosphorylates target pro-
teins, among them vasodilator-stimulated phosphoprotein (VASP)
at the serine 239 residue (32). Increased phosphorylation at serine
239 was observed specifically in rhodopsin-expressing cells and
cells undergoing cell death (Fig. S2 A and B). Ca2+-activated calpain-
type proteases and the nuclear translocation of the calpain substrate
and cell death effector AIF are important components of rd1 de-
generation, likely downstream of CNGC activation (16, 33). In
cells exposed to CN03 we found reduced serine 239 phosphoryla-
tion of VASP together with reduced Ca2+ levels (Fig. 4 A and B),
suggesting PKG and CNGC inhibition. We confirmed that
CN03 targeted PKG and not PKA by showing that VASP
phosphorylation at serine 157, a PKA phosphorylation site, was
not affected by the treatment (Fig. S2C). CN03 also decreased
calpain activation (Fig. 4C) and nuclear localization of AIF (Fig.
4D). We neither observed signs of toxicity for CN03 at 50 μM on
retinal explant cultures derived from WT animals (Fig. 4 E and
F) nor on WT-derived photoreceptor-like cells at concentrations
up to 500 μM (Fig. S3 A and B). rd1 explant cultures in vitro (Fig.
S3C) and subsequent in vivo studies in rd10 animals (Fig. S3D)
suggested 50 μM CN03 as a suitable treatment dose.
CN03 Protects Photoreceptors Carrying Different Gene Mutations. To
assess the protective capacities of CN03 in forms of RD caused
by different mutations in the same gene or in a different gene we
extended our in vitro testing to retinal explant cultures derived
from rd10 and rd2 mice. This is important, because the rd1
mutation in the Pde6b gene causes primary rod cell death already
during retinal development, with over 50% reduction of the
photoreceptor layer until P14 and an almost complete loss of
rods by P18 (8, 34). In contrast, the rd10 mouse harbors a dif-
ferent Pde6b mutation, causing slower rod degeneration com-
pared with rd1, with around 15% of the photoreceptor layer
remaining at P30 (35). The rd2 (rds) mouse carries a mutation in
the Prph2 gene, leading to absence of rod and cone outer seg-
ments, with strongly reduced retinal function, but a relatively
slow loss of both rods and cones. Around 35% of the rd2 pho-
toreceptor layer is lost until P60 (36).
Fig. 4. CN03 acts on PKG and CNGC and reduces
photoreceptor death in three different in vitro RD
models. (A–D) Photoreceptor-like cell cultures de-
rived from rd1 mice (NT, red bars) and effects of
50 μM CN03 (yellow bars) on degeneration markers
(n = 9–15 cell cultures obtained from three to five
independent preparations). (A) CN03 reduced the
phosphorylation at serine 239 of the PKG-target
VASP (pVASP, red). (B) Fluo-4, AM Ca2+ imaging
(green, arrow indicates a cell with high Ca2+) in-
dicated reduction in intracellular Ca2+. (C) Calpain
protease activity assay brightly labeled condensed
dying cells (arrows). Mean calpain labeling intensity
was reduced after CN03 treatment. (D) AIF (red)
translocation from mitochondria to nuclei (blue) and
cell death, as assessed by the TUNEL assay (green),
was restrained by CN03 treatment (triple-stained nu-
clei shown in white; see arrows). (E) CN03 (50 μM) had
no adverse effects in P11 organotypic explants de-
rived fromWT (top row). In P11 rd1, P19 rd2, and P18
rd10 explants CN03 reduced the number of dying cells
in the ONL. (F) Quantification of the data from E;
ratio (treated/NT) of TUNEL-labeled cells (NT WT, n =
2 separate retinal explant cultures; CN03 WT, 4; each
NT mutant, 4; each CN03 treated mutant, 8; rd1 data
from Fig. 2G shown for comparison). Error bars inA–D
and F: SEM. Statistical comparisons: Student’s t test
(unpaired, two-tailed). NT, not treated. (Scale bars: A–
C, 50 μm; D, 20 μm; E, 50 μm.) *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001.













We found that CN03 protected photoreceptors in both rd2 and
rd10 retinal explants in vitro (Fig. 4 E and F), thus generalizing
our rd1 findings. Since rods outnumber cones 97:3 in the mouse
retina (37), the protection observed in all three mutants is
expected to relate mainly to a preservation of rods.
Liposomal Formulation Facilitates Compound Delivery Across the
BRB. A major challenge for in vivo drug delivery to the retina is
the BRB (18, 38). To facilitate retinal drug delivery, we chose
glutathione-targeted PEGylated (GSH-PEG) liposomes, which
had previously been shown to be a safe delivery system that
Fig. 5. CN03 liposomal formulation improves neuroprotective efficacy. (A) Electron microscopy of GSH-PEG liposomes loaded with CN03 showing a vesicle
size of ∼100 nm. (B) Neuroprotective effects of CN03 (yellow; EC50 = 400 ± 5 nM) and LP-CN03 (blue; EC50 = 3.5 ± 1 nM) in rd1mutant photoreceptor-like cell
cultures (n = 9 cell cultures from three independent preparations per concentration/treatment). (C) Cell death in NT rd1 photoreceptor-like cells (red bar),
empty liposome treatment (LP, orange), coadministration of LP with free CN03 (LP+CN03, 1 μM; yellow/orange checkered), and LP-CN03 (1 μM). n = 8–
62 different cell cultures from two to three independent preparations. (D) PK study in adult rats comparing in vivo half-life of free CN03 (10 min; yellow) vs.
LP-CN03 (24 h; blue). n = 6 rats per group. (E) In vivo imaging using SLO. P10 WT mice were injected i.p. with carboxyfluorescein-loaded liposomes (LP-CF) and
analyzed at P14. Fluorescent label was present mostly in retinal vasculature. (F) Cross-sections of P14 retinae from such LP-CF–treated animals displayed
fluorescent labeling of choroidal blood vessels (chor.) but also of photoreceptors in ONL. (G–I) Three different in vivo RD mouse models were treated with
CN03 (yellow), LP only (orange), or LP-CN03 (blue), beginning at the onset of degeneration (P10, rd1; P14, rd2 and rd10; cf. Table S2). Photoreceptor survival
was assessed on ex vivo retinal tissue sections by counting photoreceptor rows in ONL. WT (green) shown for comparison. n = 4–8 animals (one eye per
animal) per time point and genotype. (G) Progression of photoreceptor degeneration in rd1 animals (red) compared with rd1 animals treated with free CN03
(yellow) and LP-CN03 (blue). (H) Progression of degeneration in NT vs. LP-CN03–treated rd2 mice. (I) Progression of degeneration in NT (red) or LP-treated
(orange) or CN03-treated (yellow) vs. LP-CN03 treated (blue) rd10 animals. Note different y axis scales in G–I to account for different degeneration kinetics.
Error bars: SEM. Statistical comparisons: C, one-way ANOVA and Newman–Keuls multiple comparison test; G–I, Student’s t test (unpaired, two-tailed). INL,
inner nuclear layer; NT, not treated. (Scale bars: A, 100 nm; E, 200 μm; F, 25 μm.) *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
E3002 | www.pnas.org/cgi/doi/10.1073/pnas.1718792115 Vighi et al.
favors the transport of cargo across the blood–brain barrier after
systemic administration (19, 39). We refer to GSH-PEG
liposome-encapsulated CN03 as LP-CN03 (Fig. 5A). The pro-
tective capacity of this nanosized compound formulation was
initially tested in rd1 photoreceptor-like cell cultures in vitro,
where LP-CN03 (EC50 = 3.5 ± 1 nM) was around 100-fold more
effective than free CN03 (EC50 = 400 ± 5 nM) in reducing rd1
cell death (Fig. 5B). This remarkable increase in efficacy was
likely due to CN03’s being encapsulated into GSH-PEG lipo-
somes, because empty liposomes alone had no consistent effect,
and free CN03 mixed with empty liposomes was significantly less
effective than LP-CN03 (Fig. 5C).
Next, we compared the in vivo bioavailability of CN03 in free
form and liposomal formulation after i.v. injection in WT rats, an
established standard for pharmacokinetic (PK) studies. The half-
life of the free CN03 compound in the blood stream was only
about 10 min, presumably because of a rapid excretion of cyclic
nucleotides via the renal system (40, 41). Encapsulation of
CN03 in liposomes (LP-CN03) prolonged in vivo half-life in the
blood stream to more than 24 h (Fig. 5D).
The efficacy of GSH-PEG liposomes for in vivo delivery to the
neuroretina was assessed by i.p. administration of liposomes
loaded with carboxyfluorescein, followed by in vivo imaging with
scanning laser ophthalmoscopy (SLO). Four days after a single
i.p. injection, fluorescence was still clearly detectable in the retina
(Fig. 5E). In retinal cross-sections carboxyfluorescein strongly la-
beled choroidal blood vessels, and the retina, especially the outer
nuclear layer (ONL), confirming successful delivery of liposomal
contents to the photoreceptors (Fig. 5F). We routinely monitored
LP-CN03–treated mice and rats in vivo and postmortem (Materials
and Methods) but could not find any macroscopic evidence for
toxic effects. Likewise, postnatal weight gains during a 2-mo-long
LP-CN03 administration were normal in both mice and rats (Fig.
S3 E and F).
Systemic Delivery of LP-CN03 Protects Photoreceptors in Three
Murine RD Models in Vivo. To evaluate in vivo protective effects
we administered the LP-CN03 systemically via i.p. injections
starting at the respective onset of degeneration in each model
and counted the number of photoreceptor rows on ex vivo retinal
sections (Fig. 5 G–I and Fig. S3 G–I). In rd1 mice, systemic
administration of free CN03 (starting at P10, once per day) had
no effect on photoreceptor survival at P14, whereas treatment
with LP-CN03 significantly increased photoreceptor numbers
(Fig. 5G and Fig. S3G). Also, in the more slowly degenerating
rd2 and rd10 models treatment with LP-CN03 (starting at P14,
once per day in rd10 and every second day in rd2) resulted in a
significant increase in the number of surviving photoreceptor
rows, compared with untreated mutant, free CN03, or LP only
(Fig. 5 H and I and Fig. S3 H and I). LP-CN03 preserved rd2
retina structurally and functionally at P30 and P60 (Fig. S4). In
relative terms, the protection observed was more striking in rd10
animals, which motivated us to evaluate this model in more
detail. We analyzed sagittal sections of P30 rd10 retina (Fig. 6A)
to survey the number of surviving photoreceptor rows as a
function of eccentricity (i.e., distance from the optic nerve).
Fig. 6. LP-CN03 partly preserves rd10 retinal mor-
phology and cone photoreceptor function at P30.
(A) P30 sagittal retinal cross-sections from NT rd10
(red) and LP-CN03–treated (blue) rd10 animals, with
insets showing higher magnification. (B) Quantifica-
tion of photoreceptor rows (P30) along the dorsal–
ventral axis, from center (optic nerve= 0°) to periphery
(90°). Colors as in A; empty liposome condition (LP)
shown in orange. (C) Representative ERG responses
(30.0 cd·s/m2, dark-adapted) in rd10 animals; NT (red),
LP-treated (orange), and LP-CN03–treated (blue).
Congenic, age-matched WT traces (green) shown for
comparison. (D) Summary plots for a- and b-wave
maximum amplitudes over different light stimulus in-
tensities. (E) Rod and cone flicker ERG responses eli-
cited by either 5-Hz scotopic flicker (0.000122 cd·s/m2)
or 10-Hz photopic flicker (30 cd·s/m2). (F) Comparison
of Fourier-transformed scotopic- and photopic-flicker
ERGs. Error bars: SEM. WT: n = 4 animals; rd10: n =
8–12 per condition (one eye per animal). Statistical
comparisons: B, Student’s t test (unpaired, two-tailed)
comparing LP-CN03 vs. LP treatment; D and F, one-way
ANOVA with Tukey’s honestly significant difference
post hoc test; NT, not treated. (Scale bars: A, 200 μm;A,
Inset, 50 μm.) *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.













Throughout the sagittal axis of LP-CN03–treated rd10 mice
photoreceptor survival was increased by at least 50%, compared
with animals that were treated with LP alone (Fig. 6B). Loss of
photoreceptors in untreated and LP-treated rd10mice was similar.
We then evaluated the effect of LP-CN03 on rd10 retinal
function in vivo using ERG. At P30, standard ERG responses to
single-flashes (30.0 cd·s/m2), recorded in dark-adapted WT mice,
measured from −350 μV (a-wave; primary photoreceptor re-
sponse) to +400 μV (b-wave; secondary inner retinal activity,
mainly bipolar cells). ERG responses of untreated rd10 animals
of the same age were much smaller, measuring from ∼−10 μV
to ∼+50 μV (Fig. 6C). Treatment with LP alone had no detect-
able effect on rd10 ERG responses. In contrast, LP-CN03 strongly
and significantly increased both a-wave (−30 μV, for the highest
light level) and b-wave responses (+250 μV) in rd10 animals. The
clearly discernible a-wave in rd10 treated animals confirmed that
CN03 did not impede cone phototransduction. Across different
light intensities, b-wave amplitudes were four- to fivefold larger in
LP-CN03–treated rd10 animals (Fig. 6D and Tables 2 and 3).
A comparison between our data and previously reported ERG
recordings from Rho−/− mice (42), in which only cones are
functional, suggests that cone function was almost completely
preserved in treated rd10 mice. To investigate this further, we
recorded scotopic (rod-driven) and photopic (cone-driven)
flicker ERGs. As expected for animals with dysfunctional rods
(due to Pde6b mutation), scotopic flicker responses in rd10—
whether treated or not—were completely abolished (Fig. 6E).
Strikingly, photopic flicker responses in LP-CN03 rd10 treated
animals appeared even larger than in WT (Fig. 6 E and F and
Table 3). A likely explanation is that with nonfunctional rd10
rods the cone-driven OFF-bipolar cell channel lacks inhibitory
input from the rod pathway, resulting in a higher net cone re-
sponse to flicker (42). Taken together, our ERG results support
evidence that LP-CN03 treatment preserved rd10 cone function
through inhibition of rod cell death.
Discussion
Here, we provide proof of principle that cGMP analogs can
counteract photoreceptor degeneration in vivo when delivered
across the BRB to their cellular target. We also demonstrate that
the preservation of rods can improve the function of cones,
lending support to the hypothesis that “sparing the rods” indeed
“saves the cones” (4).
Dysregulation of cGMP has been observed in a variety of
diseases, including neurodegeneration (34, 43, 44) and RD,
where it seems to be a common disease denominator (11). High
levels of cGMP likely cause abnormal PKG and/or CNGC ac-
tivity (17). PKG appears as an important mediator of cGMP-
dependent cell death, and its overactivation is known to cause
loss of cellular adhesion and a form of cell death reminiscent of
anoikis (45, 46). Our data show that PKG inhibition has strong
neuroprotective effects on postmitotic photoreceptors, thus
corroborating earlier findings on this theme, for instance where
reduced PKG activity increased the neuronal tolerance to stress
(47). Follow-up studies may shed further light on how PKG in-
hibition affects downstream processes and how these may pro-
mote photoreceptor survival.
With respect to the CNGC, high cGMP levels causing a
dangerous inflow of Ca2+ have long since been proposed as a key
event in photoreceptor degeneration (29). While recent data
indicate that the Ca2+ dynamics rather than the absolute in-
tracellular Ca2+ concentrations may be more relevant for the
degeneration of cones in mice (48), there is a general consensus
that excessive Ca2+ influx over prolonged periods of time (i.e., in
a chronic disease) is detrimental (15, 49). An interesting point
for future studies would be to see if cGMP analogs can selec-
tively inhibit any of the rod or cone CNGC subunits.
The fact that cGMP analogs can be tailored to limit the ac-
tivity of PKG and/or CNGC makes this class of compounds very
promising for a targeted therapy of RD. Indeed, we found that
CN03 inhibited both PKG and CNGC, probably explaining why
this compound performed so well in our test systems. In contrast,
and against prior expectations (22), CN04 and CN05 behaved as
CNGC activators, suggesting that their large R3 substituents
overruled the CNGC inhibitory effect of the R1 + R2 PET
substitution. This may also explain the lack of protection by the
dimers CN09 and CN10 with their large-molecular-size R3 sub-
stituent, linking the two cGMPS moieties.
Another aspect of our study is the administration route of
drugs to the retina. In current clinical practice most drugs tar-
geting retinal cells are locally injected into the vitreous body,
Table 2. Results of one-way ANOVA analysis conducted for each ERG stimulus condition
ERG amplitude
WT rd10 NT rd10 + LP rd10 + LP-CN03
df F Pn Mean, μV SD, μV n
Mean,
μV SD, μV n
Mean,
μV SD, μV n
Mean,
μV SD, μV
Scotopic single flash 0.0001
b-wave 8 19.85 12.54 7 16.15 11.36 8 27.45 12.96 (2, 22) 1.65 ns
Scotopic single flash 0.03
a-wave 8 −3.74 3.38 6 −7.00 4.97 8 −4.93 7.60 (2, 21) 0.57 ns
b-wave 8 26.07 15.84 7 29.96 20.41 8 69.94 43.92 (2, 22) 5.23 0.0149*
Scotopic single flash 0.3
a-wave 8 −6.71 8.33 5 −11.44 7.44 8 −6.48 6.09 (2, 20) 0.83 ns
b-wave 8 16.40 6.57 7 58.48 22.04 8 103.18 48.18 (2, 22) 15.48 <0.0001***
Scotopic single flash 3.0
a-wave 7 −12.39 7.73 7 −15.77 14.38 8 −14.58 12.47 (2, 21) 0.16 ns
b-wave 8 36.09 22.94 7 86.26 36.73 8 173.09 71.07 (2, 22) 16.27 <0.0001***
Scotopic single flash 30
a-wave 8 −11.31 7.71 5 −14.82 10.16 8 −29.85 14.08 (2, 20) 6.10 0.0095**
b-wave 8 57.36 38.05 7 81.35 55.78 8 220.80 83.16 (2, 22) 15.94 <0.0001***
Photopic single flash 3.0
a-wave 7 −2.54 3.96 6 −6.39 7.91 8 −5.16 5.27 (2, 20) 0.77 ns
b-wave 7 26.38 10.32 7 38.34 20.45 8 81.67 29.12 (2, 21) 13.46 0.0002***
Scotopic 5-Hz flicker 4 93.37 11.73 8 6.02 0.94 14 6.45 4.75 8 7.20 2.00 (3, 30) 359.87 <0.0001***
Photopic 10-Hz flicker 4 36.82 10.14 7 11.01 7.28 11 15.68 9.48 8 43.33 12.59 (3, 29) 18.33 <0.0001***
Comparison of LP-CN03 effects on ERG amplitudes at P30 in WT and rd10 mice, not treated (NT), treated with empty liposome (LP), or LP-CN03,
respectively. ns: P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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where they need to cross the BRB to exert their effects (50).
Repeated intraocular injections carry a cumulative risk for seri-
ous adverse effects, most notably endophthalmitis (51). Systemic
administration can be considered less risky for the eye as well as
more patient-friendly. Nevertheless, to avoid any hazards asso-
ciated with systemic exposure, local application of CN03 to the
eye is also a viable option. Besides the delivery as liposomal
formulation it may be possible to combine CN03 with alternative
drug delivery systems, such as poly(lactic-co-glycolic acid) for
intraocular slow release (52) or cyclodextrins for topical delivery
(53). Furthermore, the marked prolongation of its in vivo half-
life with liposomal encapsulation, and the lack of therapeutic
effect without, are in line with previous observations (19, 39) and
our findings thus stress the importance of efficient drug delivery
for the treatment of retinal diseases. Whether the efficacy of the
liposomal formulation stems predominantly from the extension
of in vivo half-life or from the improved BRB permeability needs
to be addressed in future studies that may use, for instance, in
vivo steady-state i.v. dosing. We also propose that our pharma-
cological treatment may be combined with recently developed
gene therapy approaches (54, 55) both to enhance prosurvival
treatment effects and to extend the treatment window of op-
portunity for gene therapy.
In summary, we suggest cGMP signaling as a common target
for the treatment of genetically and phenotypically divergent
types of RD. Testing in other animal models, such as Pde6a
mutants (8), could further extend the spectrum of RD genes that
may be treatable with inhibitory cGMP analogs. We have pro-
duced structures with unique and target-specific properties and
can now promote cyclic nucleotide analogs as a class of pharma-
cologically active compounds for the treatment of RD. The value
of this concept for clinical translation is supported by an orphan
drug designation for CN03, awarded by the European Medicines
Agency (EU/3/15/1462). Moreover, we have adapted a nanoscale
liposomal drug delivery vehicle to innovatively and efficiently
target the retinal photoreceptors in vivo. Indeed, we demonstrate
that drug delivery is a key factor for achieving in vivo therapeutic
success. Our approach preserves retinal function in relevant ani-
mal models, highlighting its therapeutic potential for genetically
diverse and currently untreatable blinding diseases.
Materials and Methods
For details on the chemical synthesis of cGMP analogs, determination of their
lipophilicity, and liposomal encapsulation please refer to SI Materials and
Methods. The general work flow for the in vitro and in vivo testing of cGMP
analogs is given in Fig. 1B. Further details on animals, in vitro cell and retinal
explant cultures, Ca2+ imaging, in vivo PKs, in vivo imaging and function
testing, as well as on statistical analysis are given in SI Materials and Methods.
Animals for preparation of primary retinal cell cultures were kept at
Centro Servizi Stabulario Interdipartimentale of the University of Modena
and Reggio Emilia. The protocol was approved by the Ethical Committee of
the University of Modena and Reggio Emilia (protocol no. 106 22/11/2012)
and by the Italian Ministero della Salute (346/2015-PR). Animals for in vitro
retinal explant studies were kept at the animal facilities of the Biomedical
Centre, Lund University. All procedures were evaluated by the local animal
care and ethics committees and performed in accordance with permits
M172-12, M191-14, and M92-15. Efforts were made to keep the number of





CI, μV PMean, μV SD, μV
Scotopic single flash 0.03
b-wave rd10 + LP-CN03 rd10 NT 43.87 14.90 [6.18, 81.56] 0.0209*
rd10 + LP-CN03 rd10 + LP 39.98 15.42 [0.96, 78.99] 0.0440*
rd10 + LP rd10 NT 3.89 15.42 [−35.12, 42.91] ns
Scotopic single flash 0.3
b-wave rd10 + LP-CN03 rd10 NT 86.78 15.60 [47.32, 126.24] <0.0001***
rd10 + LP-CN03 rd10 + LP 44.70 16.15 [3.86, 85.55] 0.0305*
rd10 + LP rd10 NT 42.07 16.15 [1.23, 82.92] 0.0428*
Scotopic single flash 3.0
b-wave rd10 + LP-CN03 rd10 NT 137.00 24.27 [75.59, 198.41] <0.0001***
rd10 + LP-CN03 rd10 + LP 86.83 25.13 [23.26, 150.39] 0.0067**
rd10 + LP rd10 NT 50.17 25.13 [−13.39, 113.74] ns
Scotopic single flash 30
a-wave rd10 NT rd10 + LP-CN03 18.54 5.55 [4.38, 32.70] 0.0097**
rd10 + LP rd10 + LP-CN03 15.03 6.33 [−1.11, 31.18] ns
rd10 NT rd10 + LP 3.51 6.33 [−12.64, 19.65] ns
b-wave rd10 + LP-CN03 rd10 NT 163.44 31.07 [84.85, 242.04] 0.0001***
rd10 + LP-CN03 rd10 + LP 139.45 32.16 [58.10, 220.81] 0.0009**
rd10 + LP rd10 NT 23.99 32.16 [−57.36, 105.35] ns
Scotopic 5-Hz flicker WT rd10 NT 87.35 3.04 [79.08, 95.62] <0.0001***
WT rd10 + LP 86.92 2.82 [79.27, 94.58] <0.0001***
WT rd10 + LP-CN03 86.17 3.04 [77.91, 94.44] <0.0001***
rd10 + LP-CN03 rd10 NT 1.18 2.48 [−5.57, 7.93] ns
rd10 + LP-CN03 rd10 + LP 0.75 2.20 [−5.24, 6.73] ns
rd10 + LP rd10 NT 0.43 2.20 [−5.55, 6.41] ns
Photopic 10-Hz flicker rd10 + LP-CN03 rd10 NT 32.32 5.21 [18.03, 46.61] <0.0001***
rd10 + LP-CN03 rd10 + LP 27.65 4.68 [14.82, 40.49] <0.0001***
WT rd10 NT 25.81 6.31 [8.50, 43.12] 0.0020**
WT rd10 + LP 21.15 5.88 [5.02, 37.27] 0.0068**
rd10 + LP-CN03 WT 6.51 6.16 [−10.40, 23.42] ns
rd10 + LP rd10 NT 4.67 4.87 [−8.69, 18.02] ns
ns: P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; LP, empty liposome; NT, not treated.













animals used and their suffering to a minimum. Animals for in vivo studies
were kept in the Tübingen Institute for Ophthalmic Research animal housing
facility. All in vivo procedures were performed in accordance with the local
ethics committee at Tübingen University (§4 registrations from 29 to 04-10;
30-06-10; 11-03-11; animal permit AK5/12) and the Association for Research
in Vision and Ophthalmology statement for the use of animals in ophthalmic
and visual research.
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